查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405375

硫酸軟骨素：市場佔有率分析、產業趨勢與統計、2024年至2029年成長預測

Chondroitin Sulfate - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029
出版日期: | 出版商: Mordor Intelligence | 英文 128 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

硫酸軟骨素市場規模預計到 2024 年為 13.2 億美元，預計到 2029 年將達到 15.6 億美元，在預測期內（2024-2029 年）複合年成長率為 3.36%。

硫酸軟骨素-市場-IMG1

COVID-19 大流行擾亂了硫酸軟骨素的供應鏈，使公司難以獲得製造該產品所需的原料。例如，BioMed Central 2023年4月發表的一篇論文發現，COVID-19大流行加劇了最弱勢兒童的營養不良，並增加了食品和營養原料藥的數量，包括硫酸軟骨素原料藥原料藥的供應鏈系統被擾亂。因此，疫情導致硫酸軟骨素原料藥短缺，進而導致價格上漲，導致企業生產和銷售含硫酸軟骨素的產品變得困難。

另一方面，COVID-19大流行激發了對硫酸軟骨素潛在抗病毒特性的研究，預計硫酸軟骨素將在預測期內推動市場成長。例如，Virus Journal 於 2022 年 2 月發表的一項研究強調了高度硫酸化的Glico(GAG) 衍生物（包括硫酸軟骨素 (CS)）對包括 SARS-CoV-2 在內的冠狀病毒的潛在抗病毒作用。因此，從整體情況來看，由於供應鏈中斷和隨後的價格上漲導致硫酸軟骨素原料藥短缺，COVID-19大流行在階段對市場產生了重大影響。然而，在 SARS-CoV-2 感染後，對硫酸軟骨素潛在抗病毒特性的研究增多，並探索其在新適應症中的應用，刺激了該領域的研究和投資。

預測期內促進硫酸軟骨素市場成長的關鍵因素包括通常用硫酸軟骨素治療的骨關節炎病例數量的增加、硫酸軟骨素在各個領域的應用增加等。例如，根據世界衛生組織（WHO）2023年7月發布的資料，約73%的骨關節炎患者年齡超過55歲，其中60%是女性。

此外，膝蓋和手部骨關節炎的盛行率上升，加上高齡化和肥胖症的增加，預計也將在預測期內推動市場成長。例如，健康指標與評估研究所（IHME）2023年8月發布的資料預測，到年終，全球將有約10億人患有骨關節炎，這主要是由於肥胖病例的增加。此外，根據世界衛生組織（WHO）2023年7月發布的資料，約73%的骨關節炎患者年齡超過55歲，其中60%是女性。因此，高齡化人口中骨關節炎的高盛行率預計將推動預測期內的市場成長。因此，高齡化人口中骨關節炎的高盛行率預計將推動預測期內的市場成長。

隨著世界人口高齡化，骨關節炎等與關節相關的健康問題變得越來越普遍。隨著越來越多的老年人尋求維持運動功能和控制關節不適的方法，硫酸軟骨素作為關節健康補充品的需求預計將會成長。例如，歐盟（EU）的老年人口正在快速成長。例如，世界經濟論壇2022年9月發表的報導預測，到2100年，歐盟有30%以上的人口將超過65歲。因此，世界不同地區老年人口的快速成長預計將在預測期內推動市場成長。

主要市場參與者發展硫酸軟骨素製藥業的行動預計將促進市場成長。例如，2022年3月，Livisto在埃及推出了用於治療狗和貓骨軟骨病的營養補充食品 DC。 HYALUTIDINDC 是一種由透明質酸和硫酸軟骨素組成的高度偏好的口服溶液。

因此，骨關節炎盛行率的增加和市場參與者的策略活動預計將在預測期內推動市場成長。然而，硫酸軟骨素的副作用是阻礙市場成長的主要因素。

硫酸軟骨素市場趨勢

預計藥品在預測期內將出現強勁成長

藥用級硫酸軟骨素經常被證明可以減輕骨關節炎患者的疼痛並增強其功能。硫酸軟骨素常與鹽酸鹽葡萄糖胺、硫酸葡萄糖胺、抗壞血酸錳、N-乙醯葡萄糖胺等其他物質合併使用，用於治療胃酸逆流、間質性膀胱炎、大骨節病、乳癌，用於治療膽固醇、攝護腺癌等。運動肌肉疼痛、乾癬等。硫酸軟骨素也可口服治療心臟病、愛滋病毒/愛滋病、心臟病、骨質疏鬆症和關節痛。

對於骨關節炎不適，硫酸軟骨素軟膏與硫酸鹽葡萄糖胺、鯊魚軟骨和樟腦合併使用。此外，骨關節炎患者數量的增加預計將推動研究目標市場的擴大。例如，根據美國疾病管制與預防中心 (CDC) 2021 年 9 月發布的資料，有症狀的膝骨關節炎患者的平均終生風險接近 50%。此外，根據關節炎基金會統計，到2022年，美洲將有超過3250萬人患有膝骨關節炎，5到15年間，美洲將有超過3250萬人患有前膝骨關節炎。十字韌帶( ACL) 損傷。近一半的人受到影響。預測表明，到 2040 年，將有 7800 萬美國人患有骨關節炎。因此，硫酸軟骨素具有多種醫療應用，隨著骨關節炎盛行率的增加，相應的市場預計將急劇發展。

此外，藥物製劑中硫酸軟骨素應用的擴大和採用的增加也有望促進市場成長。例如，2023年7月，工業在日本對胃腸外科領域的手術防粘連劑SI-449（主要成分為交聯硫酸軟骨素的粉末型防粘連劑）進行了重大試驗，並宣布取得了良好的成果。

因此，由於骨關節炎負擔的增加以及市場上新產品的推出等因素，預計該細分市場將顯著成長。

硫酸軟骨素-市場-IMG2

預計北美將在預測期內佔據主要市場佔有率

由於關節炎盛行率上升和硫酸軟骨素應用範圍擴大等因素，預計北美地區在預測期內將顯著成長。此外，該國市場參與者的策略活動也有望促進市場成長。

骨關節炎是一種慢性疾病，特別影響膝關節、髖關節、肩關節和手腕關節，而整形外科疾病的盛行率不斷增加是由於硫酸軟骨素等藥物的使用，這些藥物作用於疼痛並損傷關節軟骨。創造對減緩退化的有效療法的需求。這創造了對硫酸軟骨素的需求並促進了市場成長。例如，根據疾病預防控制中心2023年6月發布的統計數據，到2040年，估計有7,840萬人（25.9%）18歲及以上的美國成年人將被醫生診斷為關節炎。因此，整形外科疾病負擔的增加預計將創造對硫酸軟骨素的需求並促進市場成長。

老年人口的成長和整形外科疾病的高盛行率預計將在預測期內提高市場成長率。例如，根據聯合國人口基金發布的2022年統計數據，到2022年，加拿大約19%的人口將達到65歲或以上。因此，不斷增加的老年人口發生肌肉骨骼損傷的風險更高，增加了對硫酸軟骨素產品的需求並推動市場成長。

此外，最近在獸醫領域推出的專注於促進伴侶動物骨骼健康的產品可能會促進市場成長。例如，總部位於美國的優質狗補充品品牌Dogsnob 於2021 年3 月推出，旨在支持幼犬、成年犬和老年犬的運動表現、緩解疼痛、維持骨骼強度以及促進心臟健康。我們推出了「Mobility 」含有硫酸軟骨素的管理軟咀嚼片。預計增加對硫酸軟骨素和製造配方區域的需求的產品推出將在預測期內推動市場成長。

因此，骨質疏鬆症和關節炎等整形外科疾病負擔的增加，以及知名企業在該國推出的產品，預計將導致主要企業之間的競爭加劇。這種競爭可以帶來產品供應的改進、新的進步和價格競爭力。

硫酸軟骨素產業概況

由於存在多家在全球和區域營運的公司，硫酸軟骨素市場本質上是分散的。主要市場參與者包括 Lesaffre (Gnosis SpA)、Merck KGaA (Sigma-Aldrich Inc.)、SARIA International GmbH (Bioiberica SAU) 和 Rochem International Inc.。

其他福利：

  • Excel 格式的市場預測 (ME) 表
  • 3 個月分析師支持

目錄

第1章簡介

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場促進因素
    • 骨關節炎盛行率增加
    • 擴大硫酸軟骨素的用途
  • 市場抑制因素
    • 硫酸軟骨素的副作用
  • 波特五力分析
    • 新進入者的威脅
    • 買家/消費者的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間敵對關係的強度

第5章市場區隔（市場規模）

  • 按來源
    • 豬
    • 鯊魚
    • 牛
    • 人造的
    • 其他
  • 按用途
    • 藥品
    • 化妝品
    • 動物用藥品
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲國家
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 亞太地區其他地區
    • 中東/非洲
      • 海灣合作理事會成員國
      • 南非
      • 中東和非洲其他地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 南美洲其他地區

第6章競爭形勢

  • 公司簡介
    • SARIA International GmbH（Bioiberica SAU）
    • Rochem International Inc.
    • Lesaffre（Gnosis SpA）
    • BASIC NUTRITION
    • BeiJing Geyuantianrun Bio-tech Co. Ltd
    • Merck KGaA（Sigma-Aldrich Inc.）
    • Synutra Inc.
    • Summit Nutritionals International
    • Beloor Bayir
    • Chongqing Aoli Biopharmaceutical Co. Ltd
    • TSI Group Ltd

第7章 市場機會及未來趨勢

簡介目錄
Product Code: 67410
Chondroitin Sulfate - Market - IMG1

The Chondroitin Sulfate Market size is estimated at USD 1.32 billion in 2024, and is expected to reach USD 1.56 billion by 2029, growing at a CAGR of 3.36% during the forecast period (2024-2029).

The COVID-19 pandemic disrupted the chondroitin sulfate supply chain, making it difficult for companies to obtain the raw materials they needed to make the product. For instance, according to the article published by BioMed Central in April 2023, the COVID-19 pandemic led to an increase in malnutrition among the most vulnerable children and disrupted food and nutritional API supply chain systems, including chondroitin sulfate APIs. Thus, the pandemic led to shortages of chondroitin sulfate API, which, in turn, led to increased prices, thereby making it difficult for companies to produce and sell chondroitin sulfate-containing products.

Furthermore, the COVID-19 pandemic led to increased research studies on the potential antiviral properties of chondroitin sulfate, which is projected to drive market growth during the forecast period. For instance, a research study published by the Viruses Journal in February 2022 investigated the potential antiviral effects of high-sulfated glycosaminoglycan (GAG) derivatives, including chondroitin sulfate (CS), against coronaviruses, including SARS-CoV-2. Therefore, looking at the overall scenario, the COVID-19 pandemic substantially impacted the market in its initial phases, owing to supply chain disruptions leading to Chondroitin sulfate API shortages and subsequently increased prices. However, increased research into the potential antiviral properties of Chondroitin sulfate and the exploration of its use in new indications after SARS-CoV-2 infection has driven research and investment in this area.

The significant factors contributing to the growth of the chondroitin sulfate market over the forecast period include the rising occurrence of osteoarthritis cases, which are usually treated with chondroitin sulfate, and the increasing applications of chondroitin sulfate in various sectors. For instance, according to the data released by the World Health Organization (WHO) in July 2023, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female.

In addition, the rising prevalence of osteoarthritis of knees and hands coupled with the increasing aging population and obesity is also projected to drive market growth during the forecast period. For instance, according to the data published by the Institute for Health Metrics and Evaluation (IHME) in August 2023, approximately 1 billion people worldwide are projected to suffer from osteoarthritis by the end of 2050, primarily due to the rising obesity cases. Moreover, according to the data released by the World Health Organization (WHO) in July 2023, about 73% of people living with osteoarthritis are older than 55 years, and 60% are female. Therefore, the high prevalence of osteoarthritis in the aging population is projected to drive market growth during the forecast period. Therefore, the high prevalence of osteoarthritis in the aging population is projected to drive market growth during the forecast period.

With an aging global population, joint-related health issues like osteoarthritis are more prevalent. The demand for Chondroitin sulfate as a supplement for joint health is expected to rise as more elderly individuals seek ways to maintain mobility and manage joint discomfort. For instance, the geriatric population in the European Union (EU) is increasing at a rapid pace. For instance, as per the article published by the World Economic Forum in September 2022, more than 30% of the EU population is expected to be 65 or older by 2100. Therefore, the surging geriatric population in different regions of the world is projected to drive market growth during the forecast period.

Actions by key market players to develop the pharmaceutical segment of chondroitin sulfate are expected to boost market growth. For instance, in March 2022, Livisto launched HYALUTIDIN DC, a nutraceutical product for osteochondrosis in dogs and cats in Egypt. HyalutidinDC is an oral solution composed of hyaluronic acid and chondroitin sulfate with high palatability.

Therefore, the increasing incidence of osteoarthritis and strategic activities by market players are anticipated to drive market growth during the forecast period. However, the adverse effects of chondroitin sulfate are a major factor hindering market growth.

Chondroitin Sulfate Market Trends

The Pharmaceutical Segment is Expected to Witness Significant Growth During the Forecast Period

In patients with osteoarthritis, pharmaceutical-grade chondroitin sulfate has frequently been shown to lessen pain and enhance function. It is frequently combined with other substances, such as glucosamine hydrochloride, glucosamine sulfate, manganese ascorbate, and N-acetylglucosamine. It is used in medications to treat acid reflux, interstitial cystitis, Kashin-Beck illness, breast cancer, high cholesterol, muscle soreness after exercise, and psoriasis. Chondroitin sulfate is also taken orally for heart attack, HIV/AIDS, heart disease, osteoporosis, and joint pain.

For osteoarthritis discomfort, chondroitin sulfate ointments can be used with glucosamine sulfate, shark cartilage, and camphor. Additionally, the growing number of people with osteoarthritis is anticipated to aid in the expansion of the market studied. For instance, according to the data published in September 2021 by the Centers for Disease Control and Prevention (CDC), a person's average lifetime risk for symptomatic osteoarthritis of the knee was almost 50%. Furthermore, according to the statistics of the Arthritis Foundation, in 2022, more than 32.5 million people in the Americas will have osteoarthritis, which will impact nearly half the knees with anterior cruciate ligament (ACL) injuries during a five- to fifteen-year period. According to projections, 78 million Americans will develop osteoarthritis by 2040. Therefore, there are many different medical uses for chondroitin sulfate, and the corresponding market is anticipated to develop dramatically as incidences of osteoarthritis rise.

Moreover, the growing application of chondroitin sulfate and the increasing adoption in pharmaceutical formulations are expected to contribute to the market growth. For instance, in July 2023, Seikagaku Corporation announced that favorable results were obtained in a pivotal study in Japan for SI-449 (SI-449 is a powdered adhesion barrier whose main ingredient is cross-linked chondroitin sulfate), a surgical adhesion barrier in the field of gastroenterological surgery.

Therefore, the segment studied is expected to grow significantly owing to factors such as the increasing burden of osteoarthritis and new product launches in the market.

Chondroitin Sulfate - Market - IMG2

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America is expected to witness significant growth during the forecast period due to factors such as the rise in the prevalence of arthritis and the growing application of chondroitin sulfate. In addition, strategic activities by the market players in the country are also expected to boost market growth.

Osteoarthritis is a chronic disease that affects the knee, hip, shoulder, and hand joints in particular, and the growing prevalence of orthopedic diseases is expected to create the demand for effective treatments, such as chondroitin sulfate, which acts both on the pain and on the slowing down of the degeneration of the articular cartilage. This creates the demand for chondroitin sulfate and boosts the market growth. For instance, according to the statistics released by the CDC in June 2023, an estimated 78.4 million (25.9%) United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Hence, the growing burden of orthopedic diseases is expected to create the demand for chondroitin sulfate, thereby boosting market growth.

The increasing geriatric population is likely to increase the market growth during the forecast period as this population is highly prone to orthopedic diseases. For instance, according to the 2022 statistics published by the United Nations Population Fund, in Canada, about 19% of the population was aged 65 years and above in 2022. Thus, the growing geriatric population is at a high risk of developing musculoskeletal injuries, which raises the demand for chondroitin sulfate products and propels the market growth.

Also, recent product launches in the veterinary sector focusing on improving bone health in pet animals are likely to contribute to market growth. For instance, in March 2021, Dogsnob, a United States-based premium dog supplement brand, launched Mobility Management Soft Chews, which contain chondroitin sulfate, which is formulated to support mobility, relieve pain, maintain bone strength, and promote heart health for puppies, adults, and senior dogs. The product launches to increase the demand for chondroitin sulfate to manufacture the formulation region are expected to boost the growth of the market during the forecast period.

Therefore, the growing burden of orthopedic diseases, such as osteoporosis and arthritis, and the product launches in the country by prominent players are projected to lead to increased competition among the major players. This competition can lead to improved product offerings, new advancements, and pricing competitiveness.

Chondroitin Sulfate Industry Overview

The chondroitin sulfate market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Some of the key market players are Lesaffre (Gnosis SpA), Merck KGaA(Sigma-Aldrich Inc.), SARIA International GmbH (Bioiberica S.A.U.), and Rochem International Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Osteoarthritis
    • 4.2.2 Growing Applications of Chondroitin Sulfate
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects of Chondroitin Sulfate
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD million)

  • 5.1 By Source
    • 5.1.1 Swine
    • 5.1.2 Shark
    • 5.1.3 Bovine
    • 5.1.4 Synthetic
    • 5.1.5 Other Sources
  • 5.2 By Application
    • 5.2.1 Pharmaceuticals
    • 5.2.2 Cosmetics
    • 5.2.3 Veterinary
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 SARIA International GmbH (Bioiberica S.A.U)
    • 6.1.2 Rochem International Inc.
    • 6.1.3 Lesaffre (Gnosis SpA)
    • 6.1.4 BASIC NUTRITION
    • 6.1.5 BeiJing Geyuantianrun Bio-tech Co. Ltd
    • 6.1.6 Merck KGaA (Sigma-Aldrich Inc.)
    • 6.1.7 Synutra Inc.
    • 6.1.8 Summit Nutritionals International
    • 6.1.9 Beloor Bayir
    • 6.1.10 Chongqing Aoli Biopharmaceutical Co. Ltd
    • 6.1.11 TSI Group Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS